25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

PHE (Cipher Pharmaceuticals Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Cipher Pharmaceuticals Inc together

I guess you are interested in Cipher Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Cipher Pharmaceuticals Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Cipher Pharmaceuticals Inc’s Price Targets

I'm going to help you getting a better view of Cipher Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Cipher Pharmaceuticals Inc

I send you an email if I find something interesting about Cipher Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Cipher Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Cipher Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€3.56
Expected worth in 1 year
€4.32
How sure are you?
84.8%

+ What do you gain per year?

Total Gains per Share
€0.76
Return On Investment
8.2%

For what price can you sell your share?

Current Price per Share
€9.25
Expected price per share
€8.6 - €11.80
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Cipher Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
€9.25
Intrinsic Value Per Share
€9.23 - €10.89
Total Value Per Share
€12.79 - €14.45

2.2. Growth of Cipher Pharmaceuticals Inc (5 min.)




Is Cipher Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$102.3m$73.8m$20m21.3%

How much money is Cipher Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money$2.8m$5m-$2.2m-76.6%
Net Profit Margin42.8%95.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Cipher Pharmaceuticals Inc (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Cipher Pharmaceuticals Inc?

Welcome investor! Cipher Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Cipher Pharmaceuticals Inc.

First you should know what it really means to hold a share of Cipher Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Cipher Pharmaceuticals Inc is €9.25. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cipher Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cipher Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €3.56. Based on the TTM, the Book Value Change Per Share is €0.19 per quarter. Based on the YOY, the Book Value Change Per Share is €0.14 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cipher Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps0.131.4%0.111.2%0.202.2%0.192.1%0.141.5%0.080.9%
Usd Book Value Change Per Share0.141.5%0.212.3%0.161.7%0.212.2%0.151.6%0.121.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.141.5%0.212.3%0.161.7%0.212.2%0.151.6%0.121.3%
Usd Price Per Share10.61-8.49-3.17-4.65-3.18-2.86-
Price to Earnings Ratio20.32-69.92-4.35-26.26-18.08-12.24-
Price-to-Total Gains Ratio78.00-46.85-22.80-30.17-17.76-16.27-
Price to Book Ratio2.66-2.29-1.09-1.54-1.22-1.97-
Price-to-Total Gains Ratio78.00-46.85-22.80-30.17-17.76-16.27-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share10.3859
Number of shares96
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.210.15
Usd Total Gains Per Share0.210.15
Gains per Quarter (96 shares)20.4414.19
Gains per Year (96 shares)81.7756.78
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10827205747
201641540114104
302452360170161
403273180227218
504094000284275
604914820341332
705725640397389
806546460454446
907367280511503
1008188100568560

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%28.05.00.084.8%28.05.00.084.8%
Book Value Change Per Share4.00.00.0100.0%12.00.00.0100.0%19.01.00.095.0%28.05.00.084.8%28.05.00.084.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.033.00.0%0.00.033.00.0%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%19.01.00.095.0%28.05.00.084.8%28.05.00.084.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Cipher Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.1210.190-36%0.143-15%0.185-35%0.132-8%0.108+12%
Book Value Per Share--3.5583.264+9%2.567+39%2.496+43%1.954+82%1.485+140%
Current Ratio--1.9365.772-66%5.525-65%4.754-59%3.637-47%2.839-32%
Debt To Asset Ratio--0.3700.214+73%0.116+219%0.182+104%0.217+70%0.365+2%
Debt To Equity Ratio--0.5880.321+83%0.133+343%0.244+141%0.296+98%0.853-31%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--188477822.400165382696.200+14%63707792.700+196%90105537.000+109%58875025.027+220%45250204.029+317%
Eps--0.1160.100+16%0.181-36%0.171-32%0.126-7%0.072+60%
Ev To Sales Ratio--4.4765.957-25%3.416+31%3.887+15%2.593+73%1.921+133%
Free Cash Flow Per Share--0.3090.169+82%0.138+124%0.133+132%0.121+155%0.121+155%
Free Cash Flow To Equity Per Share--0.3050.511-40%0.090+237%0.225+35%0.162+89%0.162+89%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--10.888----------
Intrinsic Value_10Y_min--9.230----------
Intrinsic Value_1Y_max--0.613----------
Intrinsic Value_1Y_min--0.602----------
Intrinsic Value_3Y_max--2.206----------
Intrinsic Value_3Y_min--2.099----------
Intrinsic Value_5Y_max--4.239----------
Intrinsic Value_5Y_min--3.903----------
Market Cap236929500.000-2%242052300.000193705875.000+25%72327532.500+235%106157223.000+128%73002155.947+232%66134859.811+266%
Net Profit Margin--0.2830.428-34%0.958-70%0.908-69%0.655-57%0.392-28%
Operating Margin----0%0.119-100%0.217-100%0.323-100%0.342-100%
Operating Ratio--1.4060.949+48%0.720+95%0.776+81%0.710+98%0.699+101%
Pb Ratio2.600-2%2.6562.290+16%1.091+144%1.539+73%1.224+117%1.966+35%
Pe Ratio19.893-2%20.32369.922-71%4.353+367%26.257-23%18.077+12%12.240+66%
Price Per Share9.250-2%9.4507.563+25%2.824+235%4.145+128%2.836+233%2.549+271%
Price To Free Cash Flow Ratio7.493-2%7.65516.460-53%6.162+24%9.759-22%7.307+5%4.428+73%
Price To Total Gains Ratio76.354-2%78.00546.846+67%22.799+242%30.172+159%17.761+339%16.265+380%
Quick Ratio--0.6970.907-23%0.662+5%0.719-3%0.713-2%0.679+3%
Return On Assets--0.0210.027-23%0.060-66%0.061-67%0.050-59%0.030-32%
Return On Equity--0.0330.032+3%0.067-51%0.072-55%0.061-47%0.027+22%
Total Gains Per Share--0.1210.190-36%0.143-15%0.185-35%0.132-8%0.108+12%
Usd Book Value--102316505.44493873441.750+9%73833131.130+39%71797158.339+43%56742756.631+80%43303271.595+136%
Usd Book Value Change Per Share--0.1360.213-36%0.160-15%0.208-35%0.148-8%0.121+12%
Usd Book Value Per Share--3.9953.665+9%2.883+39%2.803+43%2.194+82%1.667+140%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--211622898.991185691691.293+14%71531109.644+196%101170496.944+109%66104878.101+220%50806929.083+317%
Usd Eps--0.1310.113+16%0.203-36%0.192-32%0.141-7%0.081+60%
Usd Free Cash Flow--8875701.6634874237.831+82%3962473.929+124%3819844.196+132%3528836.218+152%2138688.617+315%
Usd Free Cash Flow Per Share--0.3470.190+82%0.155+124%0.149+132%0.136+155%0.136+155%
Usd Free Cash Flow To Equity Per Share--0.3420.574-40%0.102+237%0.253+35%0.181+89%0.181+89%
Usd Market Cap266024442.600-2%271776322.440217492956.450+25%81209353.491+235%119193329.984+128%81966820.698+232%74256220.595+266%
Usd Price Per Share10.386-2%10.6108.491+25%3.171+235%4.653+128%3.185+233%2.863+271%
Usd Profit--3343134.3052885502.808+16%5094430.812-34%4878986.601-31%3542982.555-6%2052892.652+63%
Usd Revenue--11818939.5218338590.747+42%5289130.395+123%6265044.352+89%5936012.887+99%6512040.999+81%
Usd Total Gains Per Share--0.1360.213-36%0.160-15%0.208-35%0.148-8%0.121+12%
 EOD+4 -4MRQTTM+19 -16YOY+17 -193Y+18 -185Y+16 -2010Y+26 -10

3.3 Fundamental Score

Let's check the fundamental score of Cipher Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1519.893
Price to Book Ratio (EOD)Between0-12.600
Net Profit Margin (MRQ)Greater than00.283
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.697
Current Ratio (MRQ)Greater than11.936
Debt to Asset Ratio (MRQ)Less than10.370
Debt to Equity Ratio (MRQ)Less than10.588
Return on Equity (MRQ)Greater than0.150.033
Return on Assets (MRQ)Greater than0.050.021
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Cipher Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5065.796
Ma 20Greater thanMa 507.813
Ma 50Greater thanMa 1007.774
Ma 100Greater thanMa 2008.490
OpenGreater thanClose8.700
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Cipher Pharmaceuticals Inc

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. The company was founded in 2000 and is headquartered in Mississauga, Canada.

Fundamental data was last updated by Penke on 2025-05-03 12:38:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Cipher Pharmaceuticals Inc earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Cipher Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 28.3%Β means thatΒ €0.28 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cipher Pharmaceuticals Inc:

  • The MRQ is 28.3%. The company is making a huge profit. +2
  • The TTM is 42.8%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ28.3%TTM42.8%-14.6%
TTM42.8%YOY95.8%-53.0%
TTM42.8%5Y65.5%-22.7%
5Y65.5%10Y39.2%+26.3%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Cipher Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Cipher Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • 2.1% Return on Assets means thatΒ Cipher Pharmaceuticals Inc generatedΒ €0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cipher Pharmaceuticals Inc:

  • The MRQ is 2.1%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.7%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.1%TTM2.7%-0.6%
TTM2.7%YOY6.0%-3.3%
TTM2.7%5Y5.0%-2.3%
5Y5.0%10Y3.0%+1.9%
4.3.1.3. Return on Equity

Shows how efficient Cipher Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Cipher Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • 3.3% Return on Equity means Cipher Pharmaceuticals Inc generated €0.03Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cipher Pharmaceuticals Inc:

  • The MRQ is 3.3%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.2%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.3%TTM3.2%+0.1%
TTM3.2%YOY6.7%-3.5%
TTM3.2%5Y6.1%-2.9%
5Y6.1%10Y2.7%+3.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Cipher Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Cipher Pharmaceuticals Inc is operatingΒ .

  • Measures how much profit Cipher Pharmaceuticals Inc makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Cipher Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cipher Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY11.9%-11.9%
TTM-5Y32.3%-32.3%
5Y32.3%10Y34.2%-1.8%
4.3.2.2. Operating Ratio

Measures how efficient Cipher Pharmaceuticals Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.41 means that the operating costs are €1.41 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Cipher Pharmaceuticals Inc:

  • The MRQ is 1.406. The company is inefficient in keeping operating costs low. -1
  • The TTM is 0.949. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ1.406TTM0.949+0.457
TTM0.949YOY0.720+0.229
TTM0.9495Y0.710+0.239
5Y0.71010Y0.699+0.011
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Cipher Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Cipher Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.94Β means the company has €1.94 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Cipher Pharmaceuticals Inc:

  • The MRQ is 1.936. The company is able to pay all its short-term debts. +1
  • The TTM is 5.772. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ1.936TTM5.772-3.836
TTM5.772YOY5.525+0.247
TTM5.7725Y3.637+2.135
5Y3.63710Y2.839+0.798
4.4.3.2. Quick Ratio

Measures if Cipher Pharmaceuticals Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Cipher Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.70Β means the company can pay off €0.70 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cipher Pharmaceuticals Inc:

  • The MRQ is 0.697. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.907. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.697TTM0.907-0.210
TTM0.907YOY0.662+0.246
TTM0.9075Y0.713+0.195
5Y0.71310Y0.679+0.034
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Cipher Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Cipher Pharmaceuticals IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Cipher Pharmaceuticals Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.37Β means that Cipher Pharmaceuticals Inc assets areΒ financed with 37.0% credit (debt) and the remaining percentage (100% - 37.0%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Cipher Pharmaceuticals Inc:

  • The MRQ is 0.370. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.214. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.370TTM0.214+0.156
TTM0.214YOY0.116+0.098
TTM0.2145Y0.217-0.003
5Y0.21710Y0.365-0.147
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Cipher Pharmaceuticals Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Cipher Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 58.8% means that company has €0.59 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cipher Pharmaceuticals Inc:

  • The MRQ is 0.588. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.321. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.588TTM0.321+0.267
TTM0.321YOY0.133+0.188
TTM0.3215Y0.296+0.025
5Y0.29610Y0.853-0.557
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Cipher Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Cipher Pharmaceuticals Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 20.32 means the investor is paying €20.32Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cipher Pharmaceuticals Inc:

  • The EOD is 19.893. Based on the earnings, the company is fair priced.
  • The MRQ is 20.323. Based on the earnings, the company is fair priced.
  • The TTM is 69.922. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD19.893MRQ20.323-0.430
MRQ20.323TTM69.922-49.598
TTM69.922YOY4.353+65.569
TTM69.9225Y18.077+51.845
5Y18.07710Y12.240+5.837
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cipher Pharmaceuticals Inc:

  • The EOD is 7.493. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 7.655. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 16.460. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD7.493MRQ7.655-0.162
MRQ7.655TTM16.460-8.805
TTM16.460YOY6.162+10.298
TTM16.4605Y7.307+9.154
5Y7.30710Y4.428+2.878
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Cipher Pharmaceuticals Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 2.66 means the investor is paying €2.66Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Cipher Pharmaceuticals Inc:

  • The EOD is 2.600. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.656. Based on the equity, the company is underpriced. +1
  • The TTM is 2.290. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.600MRQ2.656-0.056
MRQ2.656TTM2.290+0.366
TTM2.290YOY1.091+1.200
TTM2.2905Y1.224+1.066
5Y1.22410Y1.966-0.743
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-12-312024-03-312024-06-302024-09-302024-12-31
Income before Tax  3,278-6352,643-4032,239-1,949290-2,831-2,541



6.2. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets162,512
Total Liabilities60,169
Total Stockholder Equity102,343
 As reported
Total Liabilities 60,169
Total Stockholder Equity+ 102,343
Total Assets = 162,512

Assets

Total Assets162,512
Total Current Assets38,484
Long-term Assets124,028
Total Current Assets
Cash And Cash Equivalents 17,837
Net Receivables 13,860
Inventory 5,792
Other Current Assets 995
Total Current Assets  (as reported)38,484
Total Current Assets  (calculated)38,484
+/-0
Long-term Assets
Property Plant Equipment 680
Goodwill 17,447
Intangible Assets 78,754
Long-term Assets  (as reported)124,028
Long-term Assets  (calculated)96,881
+/- 27,147

Liabilities & Shareholders' Equity

Total Current Liabilities19,874
Long-term Liabilities40,295
Total Stockholder Equity102,343
Total Current Liabilities
Accounts payable 5,873
Total Current Liabilities  (as reported)19,874
Total Current Liabilities  (calculated)5,873
+/- 14,001
Long-term Liabilities
Long term Debt 40,000
Capital Lease Obligations Min Short Term Debt578
Long-term Liabilities  (as reported)40,295
Long-term Liabilities  (calculated)40,578
+/- 283
Total Stockholder Equity
Retained Earnings 77,652
Total Stockholder Equity (as reported)102,343
Total Stockholder Equity (calculated)77,652
+/- 24,691
Other
Capital Stock27,680
Common Stock Shares Outstanding 25,589
Net Debt 22,163
Net Invested Capital 142,343
Net Working Capital 18,610
Property Plant and Equipment Gross 1,240



6.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
77,405
78,279
54,614
56,502
63,130
50,306
60,995
54,622
55,686
54,104
52,958
45,879
46,455
45,551
46,013
46,087
44,276
46,306
48,074
46,393
51,651
53,997
55,951
57,434
73,776
76,960
80,612
90,529
86,031
92,552
93,910
153,855
162,512
162,512153,85593,91092,55286,03190,52980,61276,96073,77657,43455,95153,99751,65146,39348,07446,30644,27646,08746,01345,55146,45545,87952,95854,10455,68654,62260,99550,30663,13056,50254,61478,27977,405
   > Total Current Assets 
52,169
64,073
40,329
44,260
53,854
38,103
28,654
21,937
22,935
18,861
18,510
15,966
17,230
16,997
17,423
18,137
20,129
22,358
24,289
24,610
29,327
31,838
34,113
36,204
38,161
41,629
45,250
51,762
48,273
53,601
54,959
29,058
38,484
38,48429,05854,95953,60148,27351,76245,25041,62938,16136,20434,11331,83829,32724,61024,28922,35820,12918,13717,42316,99717,23015,96618,51018,86122,93521,93728,65438,10353,85444,26040,32964,07352,169
       Cash And Cash Equivalents 
34,486
33,700
19,663
24,342
28,241
27,995
12,639
10,034
10,357
7,924
9,249
6,351
6,346
8,840
8,688
4,731
9,142
13,283
16,071
15,628
20,548
21,850
24,191
27,477
28,836
33,427
36,338
42,086
39,825
41,981
47,984
9,524
17,837
17,8379,52447,98441,98139,82542,08636,33833,42728,83627,47724,19121,85020,54815,62816,07113,2839,1424,7318,6888,8406,3466,3519,2497,92410,35710,03412,63927,99528,24124,34219,66333,70034,486
       Net Receivables 
14,644
15,175
17,821
17,400
23,606
8,003
14,164
9,648
10,470
9,099
7,832
8,176
8,878
6,982
7,211
11,741
9,220
7,550
6,328
6,939
6,658
7,804
7,334
6,218
6,802
5,487
5,824
6,701
5,088
8,433
3,776
13,215
13,860
13,86013,2153,7768,4335,0886,7015,8245,4876,8026,2187,3347,8046,6586,9396,3287,5509,22011,7417,2116,9828,8788,1767,8329,09910,4709,64814,1648,00323,60617,40017,82115,17514,644
       Inventory 
1,272
656
899
700
488
923
824
1,066
772
570
612
547
1,043
629
1,053
942
892
819
1,357
1,403
1,650
1,872
2,249
2,269
2,152
2,383
2,864
2,528
2,982
2,768
2,898
5,271
5,792
5,7925,2712,8982,7682,9822,5282,8642,3832,1522,2692,2491,8721,6501,4031,3578198929421,0536291,0435476125707721,0668249234887008996561,272
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
35,243
34,448
29,913
29,225
28,554
28,590
27,950
24,147
23,948
23,785
21,783
22,324
22,159
21,838
21,230
35,615
35,331
35,362
38,767
37,758
38,951
38,951
124,797
124,028
124,028124,79738,95138,95137,75838,76735,36235,33135,61521,23021,83822,15922,32421,78323,78523,94824,14727,95028,59028,55429,22529,91334,44835,243000000000
       Property Plant Equipment 
790
636
314
297
266
240
229
324
690
2,677
2,475
2,306
2,198
2,097
2,035
1,966
1,907
1,844
1,781
6
501
484
445
505
481
471
441
412
402
377
369
853
680
68085336937740241244147148150544548450161,7811,8441,9071,9662,0352,0972,1982,3062,4752,677690324229240266297314636790
       Goodwill 
0
0
0
0
0
0
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
15,706
17,447
17,44715,70615,70615,70615,70615,70615,70615,70615,70615,70615,70615,70615,70615,70615,70615,70615,70615,70615,70615,70615,70615,70615,70615,70615,70615,70615,706000000
       Intangible Assets 
17,582
6,436
6,374
5,601
5,400
8,384
13,460
13,805
14,130
13,933
13,721
9,998
10,378
10,139
9,913
9,686
4,178
4,045
3,913
3,780
3,647
3,514
3,381
3,068
2,754
2,451
2,126
1,885
1,763
1,503
1,244
85,972
78,754
78,75485,9721,2441,5031,7631,8852,1262,4512,7543,0683,3813,5143,6473,7803,9134,0454,1789,6869,91310,13910,3789,99813,72113,93314,13013,80513,4608,3845,4005,6016,3746,43617,582
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
35,243
34,448
29,913
29,225
28,554
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000028,55429,22529,91334,44835,243000000000
> Total Liabilities 
59,391
63,074
38,525
37,460
40,194
28,022
36,310
28,999
30,927
28,466
25,871
21,023
18,444
14,845
14,842
13,282
11,634
12,378
11,709
9,547
12,754
13,649
14,036
12,988
9,696
9,819
10,412
12,981
5,511
6,958
5,114
54,997
60,169
60,16954,9975,1146,9585,51112,98110,4129,8199,69612,98814,03613,64912,7549,54711,70912,37811,63413,28214,84214,84518,44421,02325,87128,46630,92728,99936,31028,02240,19437,46038,52563,07459,391
   > Total Current Liabilities 
20,948
42,644
17,160
16,187
27,197
17,333
22,616
17,261
21,277
18,224
17,417
16,734
16,615
13,213
13,157
11,603
9,917
10,664
10,023
9,547
12,294
13,182
13,584
12,636
9,369
9,517
10,130
12,729
5,252
6,730
4,914
14,508
19,874
19,87414,5084,9146,7305,25212,72910,1309,5179,36912,63613,58413,18212,2949,54710,02310,6649,91711,60313,15713,21316,61516,73417,41718,22421,27717,26122,61617,33327,19716,18717,16042,64420,948
       Short-term Debt 
36,521
39,500
19,611
19,724
6,664
6,664
8,065
8,000
8,069
8,000
8,000
8,000
7,620
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000007,6208,0008,0008,0008,0698,0008,0656,6646,66419,72419,61139,50036,521
       Short Long Term Debt 
36,521
39,500
19,611
19,724
6,664
6,664
8,065
8,000
8,069
8,000
8,000
8,000
7,620
5,656
3,656
1,666
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000001,6663,6565,6567,6208,0008,0008,0008,0698,0008,0656,6646,66419,72419,61139,50036,521
       Accounts payable 
15,961
12,167
11,940
9,666
10,850
7,175
8,433
5,015
7,021
5,863
5,097
5,160
4,491
5,383
6,968
4,421
4,290
5,059
1,718
2,212
2,380
3,015
2,237
5,129
4,107
4,127
4,504
7,110
4,596
0
0
5,464
5,873
5,8735,464004,5967,1104,5044,1274,1075,1292,2373,0152,3802,2121,7185,0594,2904,4216,9685,3834,4915,1605,0975,8637,0215,0158,4337,17510,8509,66611,94012,16715,961
       Other Current Liabilities 
4,945
10,477
5,220
3,838
6,050
3,494
3,064
2,433
4,143
524
1,548
912
2,380
230
279
3,611
2,962
3,703
4,886
5,332
6,693
7,584
8,443
7,413
5,161
0
5,522
0
0
0
0
0
0
0000005,52205,1617,4138,4437,5846,6935,3324,8863,7032,9623,6112792302,3809121,5485244,1432,4333,0643,4946,0503,8385,22010,4774,945
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
10,242
8,454
4,289
1,829
1,632
1,685
1,679
1,717
1,714
1,686
0
460
467
452
352
327
302
282
252
259
228
200
40,489
40,295
40,29540,48920022825925228230232735245246746001,6861,7141,7171,6791,6851,6321,8294,2898,45410,242000000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
0
3,320
3,113
1,948
1,739
1,783
1,794
1,849
1,841
1,876
0
516
524
507
446
428
403
386
353
353
323
296
752
578
57875229632335335338640342844650752451601,8761,8411,8491,7941,7831,7391,9483,1133,3200000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
2,700
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000002,700000000000
> Total Stockholder Equity
18,014
15,205
16,089
19,042
22,936
22,284
24,685
25,623
24,759
25,638
27,087
24,856
28,011
30,706
31,171
32,805
32,642
33,928
36,365
36,846
38,897
40,348
41,915
44,446
64,080
67,141
70,200
77,548
80,520
85,594
88,796
98,858
102,343
102,34398,85888,79685,59480,52077,54870,20067,14164,08044,44641,91540,34838,89736,84636,36533,92832,64232,80531,17130,70628,01124,85627,08725,63824,75925,62324,68522,28422,93619,04216,08915,20518,014
   Common Stock
16,192
17,311
17,706
17,929
18,020
18,189
18,241
18,281
18,324
18,569
18,589
18,664
18,677
18,727
18,738
18,733
18,702
18,674
18,462
18,385
18,121
17,905
17,730
17,698
17,719
0
18,281
0
0
0
0
0
0
00000018,281017,71917,69817,73017,90518,12118,38518,46218,67418,70218,73318,73818,72718,67718,66418,58918,56918,32418,28118,24118,18918,02017,92917,70617,31116,192
   Retained Earnings 
5,312
1,981
3,157
5,896
9,715
8,881
11,009
11,710
10,625
11,441
12,835
10,757
13,867
16,508
16,919
18,509
18,399
19,722
22,335
22,899
25,198
26,886
28,538
30,999
50,517
53,088
55,962
62,879
66,267
71,030
74,025
74,308
77,652
77,65274,30874,02571,03066,26762,87955,96253,08850,51730,99928,53826,88625,19822,89922,33519,72218,39918,50916,91916,50813,86710,75712,83511,44110,62511,71011,0098,8819,7155,8963,1571,9815,312
   Accumulated Other Comprehensive Income 000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000



6.4. Balance Sheets

Currency in USD. All numbers in thousands.




6.5. Cash Flows

Currency in USD. All numbers in thousands.




6.6. Income Statements

Currency in USD. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue33,363
Cost of Revenue-9,260
Gross Profit24,10324,103
 
Operating Income (+$)
Gross Profit24,103
Operating Expense-25,515
Operating Income7,848-1,412
 
Operating Expense (+$)
Research Development0
Selling General Administrative12,238
Selling And Marketing Expenses-
Operating Expense25,51512,238
 
Net Interest Income (+$)
Interest Income330
Interest Expense--
Other Finance Cost-0
Net Interest Income330
 
Pretax Income (+$)
Operating Income7,848
Net Interest Income330
Other Non-Operating Income Expenses-
Income Before Tax (EBT)2,95513,071
EBIT - interestExpense = 0
11,545
11,545
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-2,955
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax2,955
Tax Provision--8,590
Net Income From Continuing Ops11,54511,545
Net Income11,545
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-5,223-330
 

Technical Analysis of Cipher Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cipher Pharmaceuticals Inc. The general trend of Cipher Pharmaceuticals Inc is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cipher Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Cipher Pharmaceuticals Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cipher Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 9.85 < 10.80 < 11.80.

The bearish price targets are: 8.65 > 8.6 > 8.6.

Know someone who trades $PHE? Share this with them.πŸ‘‡

Cipher Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cipher Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cipher Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cipher Pharmaceuticals Inc. The current macd is 0.35702528.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cipher Pharmaceuticals Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Cipher Pharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Cipher Pharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Cipher Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartCipher Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cipher Pharmaceuticals Inc. The current adx is 26.89.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Cipher Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Cipher Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cipher Pharmaceuticals Inc. The current sar is 7.54345764.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Cipher Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cipher Pharmaceuticals Inc. The current rsi is 65.80. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Cipher Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartCipher Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cipher Pharmaceuticals Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cipher Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Cipher Pharmaceuticals Inc Daily Stochastic Oscillator ChartCipher Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cipher Pharmaceuticals Inc. The current cci is 137.77.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Cipher Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartCipher Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cipher Pharmaceuticals Inc. The current cmo is 41.52.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Cipher Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartCipher Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cipher Pharmaceuticals Inc. The current willr is -2.04081633.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Cipher Pharmaceuticals Inc Daily Williams %R ChartCipher Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cipher Pharmaceuticals Inc. The current atr is 0.38742633.

Cipher Pharmaceuticals Inc Daily Average True Range (ATR) ChartCipher Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cipher Pharmaceuticals Inc. The current obv is 5,767.

Cipher Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartCipher Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cipher Pharmaceuticals Inc. The current mfi is 75.38.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Cipher Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartCipher Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cipher Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-12-10 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-11 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-12-12 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-13 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-18 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-19 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-02 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-07 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-09 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-10 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-14 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-16 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-01-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-21 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-22 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-23 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-29 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-31 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-03 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-04 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-07 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-10 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-12 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-18 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-21 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-24 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-25 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-26 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-03 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-07 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-10 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-11 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-13 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-14 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-18 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-19 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-20 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-24 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-25 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-26 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-27 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-01 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-07 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-09 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-10 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-14 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-15 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-16 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-23 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-24 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-25 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-29 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-30 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-02 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-07 00:00:00MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside

6.3. Candlestick Patterns

Cipher Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cipher Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5065.796
Ma 20Greater thanMa 507.813
Ma 50Greater thanMa 1007.774
Ma 100Greater thanMa 2008.490
OpenGreater thanClose8.700
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Cipher Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Cipher Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cipher Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cipher Pharmaceuticals Inc

I send you an email if I find something interesting about Cipher Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cipher Pharmaceuticals Inc.

Receive notifications about Cipher Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.